Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Value-Based Cancer Care

- PMLiVE

NICE recommends Vertex/CRISPR’s Casgevy gene therapy for beta thalassaemia

An estimated 460 patients in England with severe cases of the blood disorder could be eligible for Casgevy

- PMLiVE

Equillium’s itolizumab shows promise in phase 3 graft versus host disease study

About a third of patients who have undergone a stem cell or bone marrow transplant will develop the condition

Person having information explained to him

Clarity in clinical trials

Discover how transparent, empathetic communication and health literacy principles can empower patients and enhance engagement in clinical trials, transforming participants into active partners in their healthcare journey.

Cuttsy + Cuttsy

- PMLiVE

Valneva and LimmaTech Biologics partner to advance Shigella vaccine candidate

There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally

- PMLiVE

Levicept’s NT-3 inhibitor shows promise in moderate-to-severe osteoarthritis

The degenerative joint disease affects more than 32.5 million adults in the US

- PMLiVE

WHO announces new mRNA vaccine development initiative against human avian influenza

H5N1 was responsible for 889 cases and 463 deaths across 23 countries from 2003 to 2024

Enhancing Continuity with Online Meetings – Perks of Virtual Medical Education

Explore the power of online meetings for superior continuity in our latest video from the "Perks of Virtual Medical Education" series. Learn how shorter, more frequent virtual touchpoints allow for...

Impetus Digital

- PMLiVE

Roche’s Genentech and Sangamo enter neurodegenerative disease partnership worth over $1.9bn

According to WHO, neurological conditions are now the leading cause of ill health and disability worldwide

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in phase 3 heart failure study

Almost 60% of those affected by HFpEF in the US are also living with obesity

- PMLiVE

Researchers develop immunotherapy to prevent prostate cancer treatment resistance

The second-most common cancer in the UK affects more than 52,000 men every year

- PMLiVE

Word Monster appoints Dave Taylor-Langdale as managing director

Taylor-Langdale has been serving as editorial director and marketing director at the agency

- PMLiVE

Merck and Daiichi Sankyo to jointly develop T-cell engager in deal worth over $170m

The partners will evaluate MK-6070 as part of a combination treatment for small cell lung cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links